Related Experiment Videos
Safety of moxidectin in avermectin-sensitive collies
A J Paul1, W J Tranquilli, D E Hutchens
1Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana 61802, USA.
American Journal of Veterinary Research
|May 10, 2000
Summary
Moxidectin administered at high doses (up to 30 times the recommended amount) showed no signs of toxicosis in avermectin-sensitive Collies. This suggests moxidectin has a wider safety margin compared to ivermectin or milbemycin in this sensitive breed.
Area of Science:
- Veterinary Pharmacology
- Toxicology
- Canine Medicine
Background:
- Avermectin sensitivity in Collies poses a significant risk for adverse drug reactions.
- Previous studies highlight the narrow safety margins of certain avermectins in susceptible canine breeds.
Purpose of the Study:
- To assess the safety profile of moxidectin in avermectin-sensitive Collies.
- To determine the toxicological effects of elevated moxidectin doses in this specific canine population.
Main Methods:
- Twenty-four Collies with documented ivermectin sensitivity were used.
- Dogs received oral moxidectin at 30, 60, or 90 microg/kg, or placebo.
- Clinical observations for toxicosis were conducted over a one-month period.
Main Results:
- No signs of toxicosis were observed in any dogs treated with moxidectin, even at doses 10, 20, and 30 times the recommended level.
- Control group dogs receiving placebo also showed no adverse effects.
Conclusions:
- Moxidectin demonstrates a favorable safety margin in avermectin-sensitive Collies at doses significantly exceeding the recommended therapeutic levels.
- The findings suggest moxidectin may be a safer alternative to ivermectin and milbemycin for heartworm prevention in Collies.